Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice

British Journal of Pharmacology

Volumn 166, Issue 4, 2012, Pages 1444-1460

  Izzo, Angelo A ^a,c   Capasso, Raffaele ^a,c   Aviello, Gabriella ^a,c   Borrelli, Francesca ^a,c   Romano, Barbara ^a,c   Piscitelli, Fabiana ^b,c   Gallo, Laura ^b,c   Capasso, Francesco ^a   Orlando, Pierangelo ^b,c   Di Marzo, Vincenzo ^b,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c Endocannabinoid Research Group   (Italy)

Author keywords

2 arachydonoylglycerol; anandamide; cannabichromene; cannabinoid receptors; cannabinoids; gastrointestinal transit; ileum; intestinal motility; transient receptor potential (TRP) channels; TRPA1

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ACETYLCHOLINE; ANANDAMIDE; CANNABICHROMENE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; MESSENGER RNA; N OLEOYLETHANOLAMINE; PALMIDROL; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM INFLAMMATION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ELECTROSTIMULATION; EX VIVO STUDY; FATTY ACID SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL DYSMOTILITY; INTESTINE CONTRACTION; INTESTINE TRANSIT TIME; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CANNABIS; DUODENUM; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; GENE EXPRESSION REGULATION; ILEITIS; ILEUM; JEJUNUM; MALE; MICE; MICE, INBRED ICR; MUSCLE CONTRACTION; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84861313729     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01879.x     Document Type: Article

References (88)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE, (2012). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol 165: 2598-2610.
3. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, et al,. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod 71: 1427-1430.
4. Aviello G, Matias I, Capasso R, Petrosino S, Borrelli F, Orlando P, et al,. (2008). Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med 86: 413-422.
5. Baldassano S, Zizzo MG, Serio R, Mulè F, (2009). Interaction between cannabinoid CB1 receptors and endogenous ATP in the control of spontaneous mechanical activity in mouse ileum. Br J Pharmacol 158: 243-251.
6. Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, et al,. (2012). Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol 165: 1556-1571.
7. Boesmans W, Owsianik G, Tack J, Voets T, Berghe PV, (2011). TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br J Pharmacol 162: 18-37.
8. Borrelli F, Izzo AA, (2009). Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 23: 33-49.
9. Borrelli F, Capasso F, Capasso R, Ascione V, Aviello G, Longo R, et al,. (2006). Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation. Br J Pharmacol 148: 553-560.
10. Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, et al,. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 87: 1111-1121.
11. Borrelli F, Capasso R, Severino B, Fiorino F, Aviello G, De Rosa G, et al,. (2011). Inhibitory effects of bromelain, a cysteine protease derived from pineapple stem (Ananas comosus), on intestinal motility in mice. Neurogastroenterol Motil 23: 745-e331.
12. Brierley SM, Hughes PA, Page AJ, Kwan KY, Martin CM, O'Donnell TA, et al,. (2009). The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology 137: 2084-2095.
13. Broccardo M, Improta G, Tabacco A, (1998). Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse. Eur J Pharmacol 342: 247-251.
14. Brown NK, Harvey DJ, (1990). In vitro metabolism of cannabichromene in seven common laboratory animals. Drug Metab Dispos 18: 1065-1070.
15. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, et al,. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134: 945-950.
16. Capasso R, Matias I, Lutz B, Borrelli F, Capasso F, Marsicano G, et al,. (2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129: 941-951.
17. Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, et al,. (2008a). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 154: 1001-1008.
18. Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, Zjawiony JK, et al,. (2008b). Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 155: 681-689.
19. Capasso R, Aviello G, Romano B, Borrelli F, De Petrocellis L, Di Marzo V, et al,. (2012). Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables: evidence for TRPA1-independent effects. Br J Pharmacol 165: 1966-1977.
20. Cattaruzza F, Spreadbury I, Miranda-Morales M, Grady EF, Vanner S, Bunnett NW, (2010). Transient receptor potential ankyrin-1 has a major role in mediating visceral pain in mice. Am J Physiol Gastrointest Liver Physiol 298: G81-G91.
21. Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA, (2009). The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil 21: 420-429.
22. Coruzzi G, Adami M, Guaita E, Menozzi A, Bertini S, Giovannini E, et al,. (2006). Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci 51: 310-317.
23. Coutts AA, Pertwee RG, (1998). Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus-longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca2+ and cAMP. Can J Physiol Pharmacol 76: 340-346.
24. Crist JR, He XD, Goyal RK, (2002). Both ATP and the peptide VIP are inhibitory neurotransmitters in guinea-pig ileum circular muscle. J Physiol 447: 119-131.
25. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V, (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570.
26. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, et al,. (2005). Involvement of the cannabimimetic compound, N-palmitoyl- ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154-1163.
27. Davis WM, Hatoum NS, (1983). Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen Pharmacol 14: 247-252.
28. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, et al,. (2008). Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325: 1007-1015.
29. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, et al,. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
30. De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, et al,. (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 204: 255-266.
31. Delong GT, Wolf CE, Poklis A, Lichtman AH, (2010). Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 112: 126-133.
32. Di Marzo V, (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455.
33. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, et al,. (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153: 1272-1280.
34. Doihara H, Nozawa K, Kawabata-Shoda E, Kojima R, Yokoyama T, Ito H, (2009a). Molecular cloning and characterization of dog TRPA1 and AITC stimulate the gastrointestinal motility through TRPA1 in conscious dogs. Eur J Pharmacol 617: 124-129.
35. Doihara H, Nozawa K, Kawabata-Shoda E, Kojima R, Yokoyama T, Ito H, (2009b). TRPA1 agonists delay gastric emptying in rats through serotonergic pathways. Naunyn Schmiedebergs Arch Pharmacol 380: 353-357.
36. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, et al,. (2008). Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295: G78-G87.
37. El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, et al,. (2010). Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 95: 434-442.
38. Engel MA, Leffler A, Niedermirtl F, Babes A, Zimmermann K, Filipović MR, et al,. (2011). TRPA1 and substance P mediate colitis in mice. Gastroenterology 141: 1346-1358.
39. Gertsch J, Pertwee RG, Di Marzo V, (2010). Phytocannabinoids beyond the Cannabis plant-do they exist? Br J Pharmacol 160: 523-529.
40. Hansen HS, Diep TA, (2009). N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 78: 553-560.
41. Hatoum NS, Davis WM, Elsohly MA, Turner CE, (1981). Cannabichromene and delta 9-tetrahydrocannabinol: interactions relative to lethality, hypothermia and hexobarbital hypnosis. Gen Pharmacol 12: 357-362.
42. Holzer P, (2011). Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther 131: 142-170.
43. Izzo AA, Camilleri M, (2009). Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 60: 117-125.
44. Izzo AA, Coutts AA, (2005). Cannabinoids and the digestive tract. Handb Exp Pharmacol 168: 573-598.
45. Izzo AA, Sharkey KA, (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126: 21-38.
46. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, et al,. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134: 563-570.
47. Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, et al,. (2008). Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 86: 89-98.
48. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009a). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
49. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, et al,. (2009b). Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 158: 451-461.
50. Jafri S, Pasricha PJ, (2001). Agents used for diarrhoea, constipation, and inflammatory bowel disease; agents used for biliary and pancreatic disease. In:, Hardman JG, Limbird LE, (eds). Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill: New York, pp. 1037-1058.
51. Jamontt JM, Molleman A, Pertwee RG, Parsons ME, (2010). The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160: 712-723.
52. Jiménez N, Puig MM, Pol O, (2006). Antiexudative effects of opioids and expression of kappa- and delta-opioid receptors during intestinal inflammation in mice: involvement of nitric oxide. J Pharmacol Exp Ther 316: 261-270.
53. Kimball ES, Schneider CR, Wallace NH, Hornby PJ, (2006). Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291: G364-G371.
54. Kondo T, Obata K, Miyoshi K, Sakurai J, Tanaka J, Miwa H, et al,. (2009). Transient receptor potential A1 mediates gastric distention-induced visceral pain in rats. Gut 58: 1342-1352.
55. Leal-Cardoso JH, Lahlou S, Coelho-de-Souza AN, Criddle DN, Pinto Duarte GI, Santos MA, et al,. (2002). Inhibitory actions of eugenol on rat isolated ileum. Can J Physiol Pharmacol 80: 901-906.
56. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al,. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
57. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, et al,. (2011). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162: 584-596.
58. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, et al,. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
59. McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, et al,. (2007). TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci U S A 104: 13525-13530.
60. Mechoulam R, Shani A, Edery H, Grunfeld Y, (1970). Chemical basis of hashish activity. Science 169: 611-612.
61. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al,. (2010). Potency trends of Delta(9)-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55: 1209-1217.
62. Mitrovic M, Shahbazian A, Bock E, Pabst MA, Holzer P, (2010). Chemo-nociceptive signalling from the colon is enhanced by mild colitis and blocked by inhibition of transient receptor potential ankyrin 1 channels. Br J Pharmacol 160: 1430-1442.
63. Nocerino E, Izzo AA, Borrelli F, Capasso F, Capasso R, Pinto A, et al,. (2002). Relaxant effect of capsazepine in the isolated rat ileum. Naunyn Schmiedebergs Arch Pharmacol 365: 187-192.
64. Nozawa K, Kawabata-Shoda E, Doihara H, Kojima R, Okada H, Mochizuki S, et al,. (2009). TRPA1 regulates gastrointestinal motility through serotonin release from enterochromaffin cells. Proc Natl Acad Sci U S A 106: 3408-3413.
65. Ohama T, Hori M, Ozaki H, (2007). Mechanism of abnormal intestinal motility in inflammatory bowel disease: how smooth muscle contraction is reduced? J Smooth Muscle Res 43: 43-54.
66. Penuelas A, Tashima K, Tsuchiya S, Matsumoto K, Nakamura T, Horie S, et al,. (2007). Contractile effect of TRPA1 receptor agonists in the isolated mouse intestine. Eur J Pharmacol 576: 143-150.
67. Pertwee RG, (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
68. Pol O, Puig MM, (1997). Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice. Br J Pharmacol 122: 1216-1222.
69. Pol O, Valle L, Ferrer I, Puig MM, (1996). The inhibitory effects of alpha(2)-adrenoceptor agonists on gastrointestinal transit during croton oil-induced intestinal inflammation. Br J Pharmacol 119: 1649-1655.
70. Pol O, Sasaki M, Jiménez N, Dawson VL, Dawson TM, Puig MM, (2005). The involvement of nitric oxide in the enhanced expression of mu-opioid receptors during intestinal inflammation in mice. Br J Pharmacol 145: 758-766.
71. Poole DP, Pelayo JC, Cattaruzza F, Kuo YM, Gai G, Chiu JV, et al,. (2011). Transient receptor potential ankyrin 1 is expressed by inhibitory motoneurons of the mouse intestine. Gastroenterology 141: 565-575.
72. Puig MM, Pol O, (1998). Peripheral effects of opioids in a model of chronic intestinal inflammation in mice. J Pharmacol Exp Ther 287: 1068-1075.
73. Purhonen AK, Louhivuori LM, Kiehne K, Kerman KE, Herzig KH, (2008). TRPA1 channel activation induces cholecystokinin release via extracellular calcium. FEBS Lett 582: 229-232.
74. Romano B, Capasso R, Aviello G, De Petrocellis L, Pescatore A, Izzo AA, et al,. (2010). Inhibitory effect of cannabichromene on intestinal motility in mice. 20th Annual Symposium of the International Cannabinoid Research Society (Lund, Sweden, July 23-27), P1-12.
75. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
76. Sanger GJ, (2007). Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 152: 663-670.
77. Schicho R, Storr MA, (2010). Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. Expert Rev Clin Pharmacol 3: 193-207.
78. Stintzing S, Wissniowski TT, Lohwasser C, Alinger B, Neureiter D, Ocker M, (2011). Role of cannabinoid receptors and RAGE in inflammatory bowel disease. Histol Histopathol 26: 735-745.
79. Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, et al,. (2010). Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil 22: 787-796.
80. Tubaro A, Giangaspero A, Sosa S, Negri R, Grassi G, Casano S, et al,. (2010). Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia 81: 816-819.
81. Turner CE, Elsohly MA, (1981). Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol 21: 283S-291S.
82. Turner CE, Elsohly MA, Boeren EG, (1980). Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43: 169-234.
83. Waterman SA, Costa M, (1994). The role of enteric inhibitory motoneurons in peristalsis in the isolated guinea-pig small intestine. J Physiol 477: 459-468.
84. Wirth PW, Watson ES, ElSohly MA, Seidel R, Murphy JC, Turner CE, (1980). Anti-inflammatory activity of cannabichromene homologs. J Pharm Sci 69: 1359-1360.
85. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, et al,. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453.
86. Wright KL, Duncan M, Sharkey KA, (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153: 263-270.
87. Yang J, Li Y, Zuo X, Zhen Y, Yu Y, Gao L, (2008). Transient receptor potential ankyrin-1 participates in visceral hyperalgesia following experimental colitis. Neurosci Lett 440: 237-241.
88. Yu YB, Yang J, Zuo XL, Gao LJ, Wang P, Li YQ, (2010). Transient receptor potential vanilloid-1 (TRPV1) and ankyrin-1 (TRPA1) participate in visceral hyperalgesia in chronic water avoidance stress rat model. Neurochem Res 35: 797-803.